Vnitřní lékařství 7/2020

PŘEHLEDOVÝ ČLÁNEK Biomarkery pro neendoskopické vyšetření sliznice jícnu | E19  / Vnitř Lék 2020; 66(7): e13–e19 /  VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 3. Sawas T, Killcoyne S, Iyer PG, et al. Identification of Prognostic Phenotypes of Esopha­ geal Adenocarcinoma in 2 Independent Cohorts. Gastroenterology 2018; 155: 1720–1728. 4. Kroupa R. Barrettův jícen, rizikové faktory, léčba. Interní Med 2012; 14: 104–106. 5. Freeman M, Offman J, Walter MF, et al. Acceptability of the Cytosponge procedure for detecting Barrett’s oesophagus: a qualitative study. BMJ Open 2017; 7: e013901. 6. Shaheen N, Falk GW, Iyer PG, et al. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol 2016; 111: 30–50. 7. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology gui- delines on the diagnosis and management of Barrett’s oesophagus. Gut 2014; 63: 7–42. 8. Iqbal U, Siddique O, Ovalle A, et al. Safety and efficacy of a minimally invasive cell sam- pling device (‘Cytosponge’) in the diagnosis of esophageal pathology: a systematic re- view. Eur J Gastroenterol Hepatol 2018; 30: 1261–1269. 9. Katzka AD. Recent Advances in Non-invasive Esophageal Tissue Sampling. Curr Gast- roenterol Rep 2017; 19: 9. 10. Szoka N, Fazi J. 2019. Cytosponge™ – A SAGES Technology and Value Assessment. SAGES - Society of American Gastrointestinal and Endoscopic Surgeons (online). Dostup- né z: https://www.sages.org/publications/tavac/cytosponge/ 11. Zhou Z, Kalatskaya I, Russell D, et al. Combined EsophaCap cytology and MUC2 im- munohistochemistry for screening of intestinal metaplasia, dysplasia and carcinoma. Clin Exp Gastroenterol 2019; 12: 219–229. 12. Li X, Kleeman S, Coburn SB, et al. Selection and Application of Tissue microRNAs for Nonendoscopic Diagnosis of Barrett’s Esophagus. Gastroenterology 2018; 155: 771–783. 13. Wang Z, Kambhampati S, Cheng Y, et al. Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett’s Esophagus: A Prospective Valida- tion Study. Clin Cancer Res 2019; 1: 2127–2135. 14. EsoCheck | Lucid Diagnostics | United State. Lucid Diagnostics | Biomarkers for Eso- phageal Cancer | New York (online). Copyright © 2019 Lucid Diagnostics (cit. 23.10.2019). Dostupné z: https://www.luciddx.com/esocheck 15. MoinovaHR,LaFramboiseT,LutterbaughJD,etal. IdentifyingDNAmethylationbiomarkers for non-endoscopic detection of Barrett’s esophagus. Sci Transl Med 2018; 17: pii: eaao5848. 16. Qureshi AP, Stachler MD, Haque O, et al. Biomarkers for Barrett’s esophagus – a con- temporary review. Expert Rev Mol Diagn 2018; 18: 939–946. 17. Naini VB, Souza FR, Odze DR. Barrett’s Esophagus: A Comprehensive and Contempo- rary Review for Pathologists. Am J Surg Pathol 2016; 40: e45–e66. 18. Mutační analýza genu p53 – Oddělení lékařské genetiky FN Brno. Oddělení lékařské genetiky FN Brno (online). Copyright © 2016 (cit. 25.10.2019). Dostupné z: https://geneti- kabrno.eu/vysetrujeme/mutacni-analyza-genu-p53/ 19. Chettouh H, Mowforth O, Galeano-Dalmau N, et al. Methylation panel is a diagnostic biomarker for Barrett’s oesophagus in endoscopic biopsies and nonendoscopic cytolo- gy specimens. Gut 2018; 67: 1942–1949. 20. Iyer PG, Taylor WR, JohnsonML, et al. Highly Discriminant Methylated DNAMarkers for the Non-endoscopic Detection of Barrett’s Esophagus. Am J Gastroenterol 2018; 113: 1156–1166. 21. Kailasam A, Mittal KS, Agrawal KD. Epigenetics in the Pathogenesis of Esophageal Ade- nocarcinoma. Clin Transl Sci 2015; 8: 394–402. 22. Cassandri M, Smirnov A, Novelli F, et al. Zinc-finger proteins in health and disease. Cell Death Discov 2017; 3: 17071. 23. Jia Y, Yang Y, Brock VM, et al. Methylation of TFPI-2 is an early event of esophageal car- cinogenesis. Epigenomics 2012; 4: 135–146. 24. Shivdasani RA. MicroRNAs: regulators of gene expression and cell differentiation. Blood 2006; 108: 3646–3653. 25. Slaby O, Srovnal J, Radova L, et al. Dynamic changes in microRNA expression profi- les reflect progression of Barrett’s esophagus to esophageal adenocarcinoma. Carcino- genesis 2015; 36: 521–527. 26. Konda AJV, Souza FR. Biomarkers of Barrett’s Esophagus: From the Laboratory to Cli- nical Practice. Dig Dis Sci 2018; 63: 2070–2080. 27. Fabisiak A, Bartoszek A, Kardas G, et al. Possible application of trefoil factor family peptides in gastroesophageal reflux and Barrett’s esophagus. Peptides 2019; 115: 27–31. 28. Miller MD, Thomas DS, Islam A, et al. c-Myc and Cancer Metabolism. Clin Cancer Res 2012; 18: 5546–5553. 29. Rugge M, Fassan M, Zaninotto G, et al. Aurora kinase A in Barrett’s carcinogenesis. Hum Pathol 2010; 41: 1380–1386. 30. CGB laboratoře. CGB laboratoře (online). Copyright © 2016, CGB laboratoř a.s. (cit. 20.09.2019). Dostupné z: http://www.pathology.cz/ 31. Groisman MG, Amar M, Meir A. Expression of the intestinal marker Cdx2 in the co- lumnar-lined esophagus with and without intestinal (Barrett’s) metaplasia. Mod Pathol 2004; 17: 1282–1288. 32. Lalkhen GA, McCluskey A. Clinical tests: sensitivity and specificity. Continuing Educa- tion in Anaesthesia Critical Care & Pain 2008; 8: 221–223. 33. Thota, Chak. Mass Screening for Barrett’s esophagus: Myth or Reality? Clin Gastroen- terol Hepatol 2018; 17: 610–612. 34. Kadri SR, Lao-Sirieix P, O’Donovan M, et al. Acceptability and accuracy of a non-en- doscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ 2010; 10; 341: c4372. 35. Ross-Innes CS, Debiram-Beecham I, O’Donovan M, et al. Evaluation of a minima- lly invasive cell sampling device coupled with assessment of trefoil factor 3 expressi- on for diagnosing Barrett’s esophagus: a multi-center case-control study. PLoS Med 2015; 29; e1001780. 36. Ross-Innes CS, Chettouh H, Achilleos A, et al. Risk stratification of Barrett’s oesopha- gus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol.2017; 2: 23–31. 37. Kroupa R, Konečný Š, Dolina J. Současné trendy v diagnostice a léčbě refluxní nemoci jícnu. Vnitř Lék 2018; 64: 588–594. 38. Svoboda P, Dítě P, Klvaňa P, et al. Rizikové faktory a prediktory progrese Barretova jíc- nu do adenokarcinomu. Vnitř Lék 2014; 60: 467–473.